Evidence-based Products

A monthly digest of research on company ingredients published in peer-reviewed journals

Claim: Phase 2 starch neutraliser leads to weight loss.

Published: Udani J, et al. Blocking carbohydrate absorption and weight loss: a clinical trial using Phase 2 brand proprietary fractionated white bean extract. Altern Med Rev 2004 Mar; 9(1):63-9.

Abstract: Phase 2 starch neutralizer brand bean extract product (?Phase 2?) is a water extract of a white bean (Phaseolus vulgaris) shown in vitro to inhibit the digestive enzyme alpha-amylase. Such inhibition may prevent the digestion of complex carbohydrates. Twenty-seven participants received either 1500mg Phase 2 or a placebo twice daily with meals for eight weeks in this randomised, double-blind study. The Phase 2 group lost an average of 3.79lbs (0.47lb per week) compared with the placebo group, which lost an average of 1.65lbs (0.21lb per week) ? a difference of 129 percent. Triglyceride levels in the Phase 2 group were reduced an average of 26.3mg/dL, more than three times greater than placebo (8.2mg/dL). Clinical trends were identified for weight loss and a decrease in triglycerides, although statistical significance was not reached.

Potential applications: Phase 2 shows promise as an adjunct therapy in the treatment of obesity and hypertriglyceridaemia.

More info: Pharmachem Laboratories
Tel: + 1 800 526 0609

Study claim: Pycnogenol modulates blood-sugar levels in diabetics.

Published: Liu X, et al. French maritime pine bark extract Pycnogenol dose-dependently lowers glucose in Type 2 diabetic patients. Diabetes Care 2004; 27:839.

Abstract: This open, controlled, dose-finding study recruited 18 men and 12 women, with a body mass index of 22-34. Patients received in succession 50, 100, 200 and 300mg Pycnogenol in intervals of three weeks. Fasting blood glucose was lowered until a dose of 200mg Pycnogenol was administered. Compared with baseline, 100-300mg lowered fasting glucose from 8.64 ? 0.93 to 7.54 ? 1.64mmol/L. A dose of 50mg Pycnogenol lowered postprandial glucose from 12.47 ? 1.06 to 11.16 ? 2.11mmol/L. Maximum decrease of postprandial glucose was observed with 200mg to 10.07 ? 2.69mmol/L. Insulin secretion was not affected; investigations are under way to elucidate the mechanism of glucose lowering. The decrease of endothelin-1 following supplementation points to an ameliorated function of the endothelium.

Potential Applications: Larger studies should explore Pycnogenol?s impact on mild type 2 diabetics.

More info: Natural Health Science
Tel: + 1 877 369 9934
Email: [email protected]

To submit newly published research on your company?s ingredients, please email [email protected] for details.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.